Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259867 · ClinicalTrials.gov registry record · Phase 2
Combination of TATE and PD-1 Inhibitor in Liver Cancer
A Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma, sponsored by Teclison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT03259867: Recruiting Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma, sponsored by Teclison.
NCT03259867 is a Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma that is actively recruiting participants, run by Teclison. The registered enrollment target is 54 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259867, a Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Teclison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Primary Outcome
Per RECIST 1.1 criteria
Conditions Studied
Interventions
- DRUG Nivolumab Injectable Product
- COMBINATION_PRODUCT Trans-arterial tirapazamine embolization
Study Locations (3)
California
- University of California, Irvine - Orange
Oklahoma
- University of Oklahoma Health Science Center - Oklahoma City
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT03259867 shows while recruiting
NCT03259867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab Injectable Product is the first listed.
NCT03259867 reports a single indexed study location in California, Oklahoma, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03259867 about?
NCT03259867 is a clinical study titled "Combination of TATE and PD-1 Inhibitor in Liver Cancer". This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular...
What is the current status of trial NCT03259867?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-07-01. Estimated completion is 2025-12-31.
What conditions does trial NCT03259867 study?
This clinical trial studies the following conditions: Gastric Cancer, Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03259867?
The interventions under investigation include: Nivolumab Injectable Product (DRUG), Trans-arterial tirapazamine embolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03259867?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03259867 being conducted?
This trial has 3 study locations across California, Oklahoma, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03259867's enrollment target sits among peer trials
54 116th of 153 higher than 37 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI